Pharmacokinetics of Rosuvastatin/Olmesartan Fixed-Dose Combination: A Single-Dose, Randomized, Open-Label, 2-Period Crossover Study in Healthy Korean Subjects

Clinical Therapeutics

Volumn 35, Issue 7, 2013, Pages 915-922

  Son, Hankil ^a,b   Roh, Hyerang ^a,b   Lee, Donghwan ^a,b   Chang, HeeChul ^c   Kim, JunKu ^c   Yun, Chohee ^c   Park, Kyungsoo ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

^c Daewoong Pharmaceutical Co Ltd   (South Korea)

Author keywords

Combination drug; Dyslipidemia; Hypertension; Olmesartan; Pharmacokinetics; Rosuvastatin

Indexed keywords

OLMESARTAN; ROSUVASTATIN;

ABDOMINAL DISCOMFORT; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CHILL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; DYSLIPIDEMIA; DYSPEPSIA; EPISTAXIS; FIXED DOSE COMBINATION; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; LACERATION; MALE; MAXIMUM PLASMA CONCENTRATION; MUSCLE DISEASE; NORMAL HUMAN; OPEN STUDY; PATIENT COMPLIANCE; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SINGLE DRUG DOSE; SORE THROAT; SOUTH KOREA; SPUTUM DISCOLORATION; TABLET; URTICARIA; WEAKNESS;

COMBINATION DRUG; DYSLIPIDEMIA; HYPERTENSION; OLMESARTAN; PHARMACOKINETICS; ROSUVASTATIN;

ADMINISTRATION, ORAL; ADULT; CROSS-OVER STUDIES; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FLUOROBENZENES; HEALTHY VOLUNTEERS; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PYRIMIDINES; SULFONAMIDES; TETRAZOLES; YOUNG ADULT;

EID: 84880506109     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.05.016     Document Type: Article

References (20)

1. Ames R.P. Hyperlipidemia in hypertension: causes and prevention. Am Heart J 1991, 122(4 Pt 2):1219-1224.
2. Lithell H. Hypertension and hyperlipidemia. A review. Am J Hypertens 1993, 6(11 Pt 2):303S-308S.
3. Manoria P. Olmesartan medoxomil: a clinical review. Indian Heart J 2006, 58:282-286.
4. Scott L.J., McCormack P.L. Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs 2008, 68:1239-1272.
5. Mire D.E., Silfani T.N., Pugsley M.K. A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker. J Cardiovasc Pharmacol 2005, 46:585-593.
6. Scott L.J., Curran M.P., Figgitt D.P. Rosuvastatin: a review of its use in the management of dyslipidemia. Am J Cardiovasc Drugs 2004, 4:117-138.
7. Rosenson R.S. Rosuvastatin: a new inhibitor of HMG-CoA reductase for the treatment of dyslipidemia. Expert Rev Cardiovasc Ther 2003, 1:495-505.
8. White C.M. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 2002, 42:963-970.
9. World Health Organization. WHO Drug Information. WHO Drug Information 2003;17.
10. Wilson S.A., Sanford A. Amlodipine/atorvastatin (Caduet) for preventing heart disease. Am Fam Physician 2006, 73:1067-1068.
11. Declaration of Helsinki, Ethical Principles for Medical Research Involving Human Subjects. 2008.
12. Korea Food and Drug Administration. Korea Good Clinical Practice Guidelines [in Korean]. Accessed April 11, 2013. http://www.drugsafe.or.kr/iwt/ds/ko/bbs/EgovBbs.do.
13. Crestor (rosuvastatin) tablets. Accessed April 11, 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/21366slr005lbl.pdf.
14. Benicar (olmesartan medoxomil) tablets. Accessed April 11, 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021286s023lbl.pdf.
15. Korea Food and Drug Administration. Bioequivalence Guideline in Korea [in Korean]. Accessed April 11, 2013. http://www.kfda.go.kr/index.kfda?mid=226&pageNo=1&seq=139&cmd=v.
16. National Institute of Toxicological Research. Guideline on Food-Effect Bioavailability and Fed Bioequivalence Studies [in Korean]. Accessed April 11, 2013. http://www.kfda.go.kr/index.kfda?mid=50%26seq=2207%26cmd=v.
17. Hull C.K., Martin P.D., Warwick M.J., Thomas E. Quantification of the N-desmethyl metabolite of rosuvastatin in human plasma by automated SPE followed by HPLC with tandem MS detection. J Pharm Biomed Anal 2004, 35:609-614.
18. Hull C.K., Penman A.D., Smith C.K., Martin P.D. Quantification of rosuvastatin in human plasma by automated solid-phase extraction using tandem mass spectrometric detection. J Chromatogr B Analyt Technol Biomed Life Sci 2002, 772:219-228.
19. Liu D., Hu P., Matsushima N., et al. Quantitative determination of olmesartan in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2007, 856:190-197.
20. Korea Food and Drug Administration. Considerations in Combination Drug Development: Anti-Hypertensive Drugs [in Korean]. Accessed May 15, 2013. http://drug.kfda.go.kr/Data/KO_DU/20100803175003_0.pdf.